Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer.

Next Previous
Trial Profile

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temsirolimus (Primary) ; Diphenhydramine; Diphenhydramine
  • Indications Prostate cancer
  • Focus Pharmacodynamics

Most Recent Events

  • 01 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 04 Jun 2010 One patient had been enrolled by December 2009 according to information presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010).
  • 14 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top